Succesful treatment of chronic hepatitis C virus infection with daclatasvir and asunaprevir in a transfusion dependent thalassaemia patient
Journal | Volume 79 - 2016 |
Issue | Fasc.4 - Letters |
Author(s) | Hayretdin Köklü, Seyfettin Köklü, Omer Ozturk, Evrim Kahramanoglu Aksoy, Nomingerel Tseveldorj |
Full article |
VIEW FREE PDF |
Hacettepe University School of Medicine, Department of Internal Medicine, Division of Gastroenterology, Ankara, Turkey |
Thalassaemia is one of the most common inherited hemoglobinopathies that is characterized with defective hemoglobin synthesis and ineffective erythropoiesis. Chronic transfusion therapy which increases the risk of hepatitis C virus (HCV) infection is the main treatment for severe forms of disease. Upon routine implementation of HCV screening in blood banks, chronic Hepatitis C incidance in thalassaemia patients has decreased. Nevertheless, HCV prevalence in transfusion dependent thalassemia patients, most of whom have acquired HCV prior to screening, is 23-47%. Cirrhosis occurs in about 10-20% of chronically infected patients. Iron overload associated with chronic transfusion also contributes to the development of cirrhosis in these patients. Therefore successful treatment of hepatitis C in thalassemia patients is imperative. |
© Acta Gastro-Enterologica Belgica. PMID 28209112 |